文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

靶向多黏菌素B血液灌流对脓毒性休克伴内毒素升高患者28天死亡率的影响:EUPHRATES随机临床试验

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

EUPHRATES多中心随机对照试验纳入450例脓毒性休克且内毒素活性≥0.60的成人重症患者,比较多黏菌素B血液灌流联合常规治疗与假灌流联合常规治疗的28天死亡率。结果显示两组28天死亡率无显著差异,MODS>9亚组同样无差异,且治疗组严重不良事件报告率更高。

要点

  • 多黏菌素B血液灌流未降低脓毒性休克伴高内毒素活性患者的28天死亡率。
  • MODS>9的预设亚组中,治疗组与假灌流组的28天死亡率也无显著差异。
  • 治疗组严重不良事件报告率为65.1%,假灌流组为57.3%。

核心结论

  • 在脓毒性休克且内毒素活性高的患者中,多黏菌素B血液灌流联合常规治疗相比假灌流联合常规治疗未降低28天死亡率。

研究设计与样本

  • 多中心、随机临床试验,于2010年9月至2016年6月在北美55家三级医院纳入450例脓毒性休克且内毒素活性测定水平≥0.60的成人重症患者。
  • 干预组接受两次多黏菌素B血液灌流(每次90-120分钟)加标准治疗,对照组接受假灌流加标准治疗,均在入组24小时内完成。
  • 主要结局为全部随机患者的28天死亡率,以及MODS>9的随机患者的28天死亡率。

主要发现

  • 共报告264例严重不良事件,治疗组65.1% vs 假灌流组57.3%;最常见为脓毒症恶化(10.8% vs 9.1%)和脓毒性休克恶化(6.6% vs 7.7%)。

临床怎么用

  • 不推荐对脓毒性休克伴内毒素活性升高的患者常规使用多黏菌素B血液灌流以改善28天生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. OBJECTIVE: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. INTERVENTIONS: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). MAIN OUTCOMES AND MEASURES: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. RESULTS: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P = .49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P = .92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). CONCLUSIONS AND RELEVANCE: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01046669.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018. PMID: 30304428. doi:10.1001/jama.2018.14618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。